爱尔兰自2022年以来在囚犯减重药物上花费70万欧元,引发关于保健公平的辩论。 Ireland spent €70K on weight-loss drugs for prisoners since 2022, sparking debate over healthcare fairness.

自2022年以来,爱尔兰在诸如Ozempic、Mounjaro和Saxenda等减重药物上为囚犯花费了70 000多欧元,仅Ozempic就花费了57 000欧元。 Ireland has spent over €70,000 on weight-loss drugs like Ozempic, Mounjaro, and Saxenda for prisoners since 2022, with €57,000 alone on Ozempic. 这笔资金通过信息自由披露,引发了关于保健公平的辩论,因为由于费用高昂,公众基本上仍无法获得这些药品。 The funding, revealed through Freedom of Information, has sparked debate over healthcare equity, as these medications remain largely inaccessible to the public due to high costs. 包括Cork TD Ken O'Flynn在内的批评者质疑向囚犯提供由纳税人出资的探视机会的公平性,而许多监狱外的人却在为他们提供探视机会而苦苦挣扎,他们要求透明和一贯的公共卫生政策。 Critics, including Cork TD Ken O’Flynn, question the fairness of providing taxpayer-funded access to inmates while many outside prison struggle to afford them, calling for transparency and consistent public health policies.